POLL: Do You Utilize the 40-GEP Test for High Risk cSCC?

A poster presentation from the 2023 Fall Clinical Dermatology Conference held October 19-22, 2023, determined that the 40-gene expression profile (40-GEP) test identified patients who benefited the most from adjuvant radiation therapy (ART) with improved metastasis-free survival and delay or abrogation of nodal or distant metastasis of cutaneous squamous cell carcinoma (cSCC).¹

High-risk cutaneous squamous cell carcinoma

Image courtesy of the Waikato District Health Board and DermNetZ

Arron et al's first matched cohort analysis demonstrated benefit (50% increase) from ART for patients with a class 2b cSCC for 5-year metastasis-free survival. The study authors also determined that class 2b results were the only factor in their study that identified patients that will benefit from ART, compared to clinicopathologic risk factors or risk assessment systems.

The authors concluded that the 40-GEP is ideal for identifying patients who will benefit from ART with improved metastasis-free survival and delay of nodal or distant metastasis, patients who are less likely to benefit from ART in controlling metastatic disease progression, and patients who will benefit from ART as a reduction in metastatic disease progression.

Reference

1. Arron S, Cañueto J, Siegel J, et al. Association of a 40-gene expression profile (40-GEP) with risk of metastatic disease progression of cutaneous squamous cell carcinoma (cSCC) and benefit of adjuvant radiation therapy (ART). Presented at: 2023 Fall Clinical Dermatology Conference; October 19-22, 2023; Las Vegas, NV.